AbbVie Inc (ABBV)vsExagen Inc (XGN)
ABBV
AbbVie Inc
$261.74
+1.79%
HEALTHCARE · Cap: $454.36B
XGN
Exagen Inc
$7.03
+0.86%
HEALTHCARE · Cap: $183.63M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 90429% more annual revenue ($64.39B vs $71.12M). ABBV leads profitability with a 9.8% profit margin vs -26.6%. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
XGN
Avoid25
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-69.4%
Fair Value
$151.82
Current Price
$261.74
$109.92 premium
Margin of Safety
+51.3%
Fair Value
$6.77
Current Price
$7.03
$0.26 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 40.0%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
15.9% revenue growth
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
Trading at 13.8x book value
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.52 suggests the stock is reasonably priced for its growth.
Bull Case : XGN
The strongest argument for XGN centers on Revenue Growth. Revenue growth of 15.9% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 72.0x leaves little room for execution misses.
Bear Case : XGN
The primary concerns for XGN are Price/Book, EPS Growth, Market Cap. Debt-to-equity of 2.09 is elevated, increasing financial risk.
Key Dynamics to Monitor
ABBV profiles as a value stock while XGN is a growth play — different risk/reward profiles.
XGN carries more volatility with a beta of 2.10 — expect wider price swings.
XGN is growing revenue faster at 15.9% — sustainability is the question.
ABBV generates stronger free cash flow (3.2B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (73/100 vs 25/100) and 10.2% revenue growth. XGN offers better value entry with a 51.3% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Exagen Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Exagen Inc. develops and markets various test products based on its Cell-Bound Complement Activation Products technology under the AVISE brand name in the United States. The company is headquartered in Vista, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?